Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
Public ClinicalTrials.gov record NCT02736955. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
Study identification
- NCT ID
- NCT02736955
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Enrollment
- 161 participants
Conditions and interventions
Conditions
Interventions
- Valbenazine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2016
- Primary completion
- Jun 29, 2017
- Completion
- Jun 29, 2017
- Last update posted
- Dec 18, 2018
2016 – 2017
United States locations
- U.S. sites
- 27
- U.S. states
- 15
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Anaheim | California | — | — |
| Not listed | National City | California | — | — |
| Not listed | Norwalk | California | — | — |
| Not listed | Oakland | California | — | — |
| Not listed | San Bernardino | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Torrance | California | — | — |
| Not listed | Hialeah | Florida | — | — |
| Not listed | North Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Cedarhurst | New York | — | — |
| Not listed | Dayton | Ohio | — | — |
| Not listed | Shaker Heights | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Norristown | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Franklin | Tennessee | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | DeSoto | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Irving | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Petersburg | Virginia | — | — |
| Not listed | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02736955, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2018 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02736955 live on ClinicalTrials.gov.